Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,645 across all filing types
Latest filing 2025-08-01 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for August 6, 2025, where the board will consider and approve the unaudited financial results for the quarter ended June 30, 2025, and fix the record date for dividend eligibility. It is an intimation to the stock exchanges and shareholders about the meeting date and agenda, not the actual financial results or report. The document is short (2117 characters) and serves as an announcement rather than containing substantive financial data or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about a board meeting and upcoming financial results approval, not the financial report itself or a detailed management discussion.
2025-08-01 English
Morepen Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2025 ,inter alia, to consider and approve unaudited financial results ....
Regulatory Filings Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for August 6, 2025, where the board will consider and approve the unaudited financial results for the quarter ended June 30, 2025, and fix the record date for dividend eligibility. It is an intimation to the stock exchanges about the board meeting date and agenda, including closure of the trading window. The document does not contain any financial data or results itself, nor is it a full report. It is a regulatory announcement about a board meeting and related procedural matters. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notice, not as an Interim Report or Earnings Release or Board/Management Information (which typically involves changes in personnel).
2025-08-01 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It details significant corporate restructuring transactions involving the sale of shares in a subsidiary (Dr. Morepen Limited) and acquisition of shares in another company (Groom Town Private Limited). The document includes quantitative and qualitative effects of these transactions on shareholding patterns and mentions valuation reports by independent valuers. The content focuses on corporate actions affecting shareholding and ownership structure rather than financial results, earnings, or management commentary. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy solicitation, voting results, or remuneration report. The document is a regulatory announcement about material corporate restructuring and shareholding changes, fitting the category of Capital/Financing Update (CAP). The document length is substantial (over 12,000 characters) and contains detailed transaction information, not merely an announcement of a report, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2025-07-31 English
Please find attached the file
Regulatory Filings Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It details significant corporate restructuring transactions involving the sale of shares in a subsidiary and acquisition of another company by the subsidiary. The document includes quantitative and qualitative effects of these transactions on shareholding patterns and mentions valuation reports by independent valuers. The content is focused on informing the market and regulators about these material events and changes in shareholding, consistent with regulatory disclosure requirements. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full report but a regulatory announcement of material corporate actions and shareholding changes. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-07-31 English
General Updates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the formation of a step-down subsidiary company by Morepen Laboratories Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content includes details about the new subsidiary, its shareholding structure, and incorporation plans. There are no financial statements, earnings data, or detailed reports; rather, it is an announcement of a corporate event (formation of a subsidiary). The document length is 4614 characters, which is relatively short and consistent with a regulatory announcement. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a corporate event that does not fit into more specific categories like M&A or Capital/Financing Update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-07-25 English
Please find attached the file
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the formation of a step-down subsidiary company by Morepen Laboratories Limited. It references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content details the approval by the board of a subsidiary to form a new wholly owned subsidiary, including specifics about shareholding, incorporation, and business purpose. The document is an announcement of a corporate event (formation of a subsidiary) rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The document length is 4614 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement about a corporate event that does not fit into more specific categories like MANG (management changes) or CAP (capital/financing update).
2025-07-25 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.